Innovus Pharmaceuticals, Inc.

19 articles with Innovus Pharmaceuticals, Inc.

• Innovus Pharma to Present at H.C. Wainwright 20th Annual Global Investment Conference

  8/29/2018

  Innovus Pharmaceuticals, Inc. today announced that Dr. Bassam Damaj, President & Chief Executive Officer, and Ryan Selhorn, Vice President, Chief Financial Officer, will present at the 2018 H.C. Wainwright 20th Annual Global Investment Conference

• Innovus Pharma Signs Purchase Agreement with “Showcase – The Home of the Hottest Trends” to Sell the Company’s Apeaz® Cream for the Relief of Arthritis Pain in Its 110 “Showcase” Retail Stores in the United States and Canada

  8/10/2018

  Apeaz® is the Fifth Company Product to Be Sold in Retails Stores in the U.S. and Canada

• Innovus Pharma Announces Three Regulatory Filings with Health Canada for Its Products: Xyralid® Suppositories, Beyond Human® Testosterone and RecalMax™

  8/7/2018

  The Three Potential Products, If Approved, Will Supplement the Company’s Eight Products Launched in Canada to Date

• Innovus Pharmaceuticals to Release Its Second Quarter 2018 Financial Results on Tuesday, August 14, 2018

  8/3/2018

  Innovus Pharmaceuticals, Inc. announced that the Company will release its June 30, 2018 second quarter financial results on Tuesday, August 14, 2018, after the close of the U.S. financial markets.

• Innovus Pharma Signs Purchase Agreement with CVS Pharmacy, Inc. to Sell Its Product Androferti® to Increase Sperm Quality in Their Newly Established In-Store Men’s Clinic

  7/19/2018

  CVS Men’s Health Clinic Pilot Program to Promote Androferti® in 12 to 20 Stores with the Potential, if Successful, to Expand Nationwide and Add Additional Products

• Innovus Pharmaceuticals Reports Preliminary Q2 2018 Sales Revenue of $6.6 million to $6.8 million

  7/17/2018

  Preliminary Quarterly Revenue Increase of 47-51% and Comparable 2017 Second Quarter Increase of 330-340% and Fiscal Year 2018 Net Revenue Annual Guidance Adjusted Upwards to at Least $22 Million

• Innovus Pharmaceuticals, Inc.: Strong Growth in the OTC Personal Care Market -- SECFilings.com

  6/22/2018

  SECFilings.com announces the publication of an article covering Innovus Pharmaceuticals Inc. 

• Innovus Pharma Announces the Launch of Its Product AllerVarx™ in Canada for Allergic Rhinitis

  6/6/2018

  AllerVarx™ is the Ninth Innovus Pharma Product Launched in Canada to Date

• Innovus Pharma Announces the Approval of Its Product ProstaGorx™ in Canada for Benign Prostatic Hyperplasia (“BPH”)

  6/4/2018

  Innovus Pharmaceuticals, Inc. announced the approval by Health Canada of its product ProstaGorx™ as a Natural Health Product (NPN #80085717) for the relief of urologic symptoms.

• Innovus Pharma Chief Executive Officer to Present at 8th Annual LD Micro Invitational Conference

  5/31/2018

  Innovus Pharmaceuticals, Inc. announced that Dr. Bassam Damaj, its President and Chief Executive Officer, will speak at the 8th Annual LD Micro Invitational Conference.

• Innovus Pharmaceuticals to Release Its First Quarter 2018 Financial Results on Monday, May 14, 2018

  5/4/2018

  Innovus Pharmaceuticals, Inc. announced that the Company will release its March 31, 2018 first quarter financial results on Monday, May 14, 2018.

• Innovus Pharma Announces the Launch of its Hemorrhoid Drug Xyralid® in Canada

  4/26/2018

  Xyralid®, a Lidocaine-based Cream for the Relief of Pain and Symptoms Caused by Hemorrhoids, is the Sixth Innovus Pharma Product launched in Canada to Date

• Innovus Pharma Expands its Senior Management with the Addition of Ryan Selhorn, CPA, as its Vice President, Chief Financial Officer

  4/23/2018

  Industry Veteran to Lead Company’s Financial and Accounting Operations into its Expanding Revenue Growth Stage

• Innovus Pharma Announces U.S. Food and Drug Administration Clearance of its GlucoGorx™ Glucose Monitoring Device Test Kit

  4/12/2018

  Innovus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s GlucoGorx™ Glucose Monitoring Test Kit that includes a glucose meter, test strips and lancet device (“GlucoGorx™ Kit”) under the 510(k) filing of its manufacturing partner, ACON Laboratories, Inc. (“ACON”) Innovus Pharma will offer the GlucoGorx™ Kit.

• Acerus Announces Launch of URIVARX® in Canada

  4/9/2018

  Acerus had previously planned for the Canadian launch of URIVARX® in the second half of 2018, but the Company has arranged for the product to be available in Canada via the Innovus supply chain.

• Innovus Pharmaceuticals Reports Record Annual Revenue for Fiscal 2017 of $8.8 Million, Preliminary Q1 2018 Revenue of $4.3 Million to $4.4 Million and Expects to Exit 2018 Profitable

  4/2/2018

  Year over Year Revenue Increase of 83% with Reduction in Net Loss of 53% in 2017 and Fiscal Year 2018 Net Revenue Annual Run Rate of At Least $18 million

• Innovus Pharma’s AllerVarx™ Receives Commercial Approval by Health Canada for the Reduction in Symptoms of Seasonal Allergic Rhinitis

  2/28/2018

  AllerVarx™ is the Eighth Innovus Pharma Product approved in Canada to date

• Innovus Pharma Launches its New Brand, Logo and its Latest E-Commerce-Enhanced Content Website

  2/27/2018

  New Website Features its Robust Beyond Human® Sales & Marketing Platform

• Innovus Pharma Announces the Complete Repayment in Cash of its Financial Obligations from its Acquisition of its Beyond Human® Assets

  2/22/2018

  Payoff in Cash of Outstanding Secured Promissory Note with SBI Investments, LLC also Releases Lien on Company’s Beyond Human® Assets and the Related Revenues